Filters

Phase
    Intervention Type
      Status
        Location:
        LocationClose
        Distance
          Term Search
          You can select from the dropdown list OR enter your own terms to refine the search.

          Last Updated: 10/31/2025

          Need to find the closest trial?
          Sort By Distance
          Save trials for later
          Sign Up
          Not sure about your diagnosis?
          Check Your Symptoms
          2 clinical trials found

            A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE

            A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE

            Who is this study for: Patients with Erosive Esophagitis
            Enrollment Status: Recruiting
            Publish Date: October 07, 2025
            Intervention Type: Drug
            Study Drug: Dexlansoprazole
            Study Phase: Phase 2

            Summary: Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth ...

            A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

            A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

            Who is this study for: Pediatric patients aged 2 to 11 years with symptomatic nonerosive gastroesophageal reflux disease
            Enrollment Status: Recruiting
            Publish Date: November 13, 2024
            Intervention Type: Drug
            Study Drug: Dexlansoprazole
            Study Phase: Phase 2

            Summary: Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth ...

            Showing 1-2 of 2

            Last Updated: 10/31/2025